LEVEL 4 N03AF01

Δραστικές

Φάρμακα

  • DRUGBANK - Carbamazepine
  • indication:

    For the treatment of epilepsy and pain associated with true trigeminal neuralgia.

  • pharmacology:

  • mechanism:

    Carbamazepine inhibits sustained repetitive firing by blocking use-dependent sodium channels. Pain relief is believed to be associated with blockade of synaptic transmission in the trigeminal nucleus and seizure control with reduction of post-tetanic potentiation of synaptic transmission in the spinal cord. Carbamazepine also possesses anticholinergic, central antidiuretic, antiarrhythmic, muscle relaxant, antidepressant (possibly through blockade of norepinephrine release), sedative, and neuromuscular-blocking properties.

  • toxicity:

    Mild ingestions cause vomiting, drowsiness, ataxia, slurred speech, nystagmus, dystonic reactions, and hallucinations. Severe intoxications may produce coma, seizures, respiratory depression, and hypotension

  • absorprion:

  • halflife:

    25-65 hours

  • roouteelimination:

  • volumedistribution:

  • clearance: